Treatment with the novel pan-PI3K/mTOR inhibitor paxalisib in combination with immunotherapy and chemotherapy led to an 86% reduction in tumor burden in a patient with metastatic triple-negative breast cancer (TNBC), according to data derived from an... [3456 chars].. reed more
